Kornimate/medical-research-clean huggingface dataset:
evaluation of one-day polyethylene glycol powder solution for colonoscopy in children

Conditions: Water-Electrolyte Imbalance

Summary: the purpose of this study is to examine the effects of current standard of care polyethylene gylcol powder (peg-p)colonoscopy preparation on a patient's serum electrolytes, tolerance of the prep, and how well the bowel is cleansed. the primary aim is to determine the proportion of patients with clinically significant serum electrolyte abnormalities at the time of colonoscopy and how well the prep is tolerated. secondary objectives include: 1) how well the bowel is cleansed with this preparation, and 2) to determine the most effective way to communicate instructions about the bowel preparation with the child and family.

design is prospective, descriptive observational study involving a single clinical encounter in the endoscopy suite at chop main at the time of colonoscopy. patients prescribed the standard of care dosage for peg-p by their primary gastroenterologist are considered for this study. study procedures include collection of data from patients that are prescribed the peg-p dose. in order to evaluate the safety, tolerability, and adherence to peg-p bowel preparation, data collections include the following: review of medical records, tracking of communication from subjects/parents, blood draw, questionnaire and quality of prep will be assessed. questionnaire results will be obtained at the initial and only visit. patients will be given a questionnaire prior to colonoscopy to rate symptoms, ease of preparation and to rate the effectiveness of communication about the preparation. on the day of colonoscopy, prior to the procedure, patients will have an iv placed per standard procedure. at the time of iv placement, a basic metabolic panel and serum magnesium and phosphorus levels will be drawn through the iv for assessment of electrolyte abnormalities. serum glucose will be captured from medical records as this is collected with standard of care. patient/parents will grade the preparation tolerance filling out a questionnaire prior to colonoscopy. during colonoscopy, the endoscopist will grade the quality of preparation on a validated residual stool survey (aronchick scale).

Eligibility criteria:
inclusion criteria: * subjects age 1 - 18 years * patients receiving standard of care dosing for polyethylene glycol powder * patients who had electrolyte results within the last 60 days of enrollment * parental / guardian permission (informed consent) exclusion criteria: * patients on the gi inpatient or consult service * weight less than 10 kg * pregnant or lactating females * non-english speaking patient or parent * 5) parents/guardians or subjects who, in the opinion of the investigator/study team, may be non-compliant with study schedules or procedures
biological therapy in treating patients with metastatic melanoma or metastatic kidney cancer

Conditions: Kidney Cancer; Melanoma (Skin)

Summary: rationale: biological therapies such as flt3l and cd40-ligand use different ways to stimulate the immune system and stop cancer cells from growing. biological therapy may be an effective treatment for metastatic melanoma and metastatic kidney cancer. purpose: phase i trial to study the effectiveness of flt3l combined with cd40-ligand in treating patients who have metastatic melanoma or metastatic kidney cancer.

objectives: i. determine the maximum tolerated dose of cd40-ligand when combined with fixed-dose flt3 ligand in patients with metastatic melanoma or renal cell cancer. outline: this is a dose-escalation study of cd40-ligand. patients receive fixed-dose flt3 ligand subcutaneously (sc) daily on days 1-14 and cd40-ligand sc daily on days 12-16. treatment continues every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. cohorts of 3 to 6 patients receive escalating doses of cd40-ligand until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. patients with progressive disease after 2 courses may be eligible to receive high-dose interleukin-2 (il-2) standard therapy. projected accrual: a total of 5 patients were accrued for this study.

Eligibility criteria:
disease characteristics: histologically confirmed metastatic renal cell cancer or melanoma measurable disease patient characteristics: age: 16 and over performance status: ecog 0-1 life expectancy: more than 3 months hematopoietic: wbc at least 3,000/mm3 platelet count at least 90,000/mm3 no coagulation disorders hepatic: bilirubin no greater than 1.6 mg/dl ast and alt less than 2.5 times normal hepatitis b surface antigen negative renal: creatinine no greater than 2.0 mg/dl cardiovascular: no major active medical illness of the cardiovascular system (e.g., cardiac ischemia, myocardial infarction, or cardiac arrhythmia) pulmonary: no major active medical illness of the respiratory system (e.g., obstructive or restrictive pulmonary disease) other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no active systemic infections no history of autoimmune disorders hiv negative prior concurrent therapy: biologic therapy: at least 3 weeks since prior biologic therapy no prior systemic flt3 ligand or cd40-ligand chemotherapy: at least 3 weeks since prior chemotherapy endocrine therapy: at least 3 weeks since prior endocrine therapy no concurrent systemic steroids radiotherapy: prior localized radiotherapy for renal cell cancer or melanoma allowed surgery: prior surgery for renal cell cancer or melanoma allowed

Keywords: stage iv renal cell cancer recurrent renal cell cancer stage iv melanoma recurrent melanoma
safety study of peptide cancer vaccine to treat hla-a*02-positive advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of hla-a\*0201 or hla-a\*0206 restricted epitope peptides urlc10 emulsified with montanide isa 51 for advanced non-small cell lung cancers.

the investigators previously identified three novel hla-a\*0201 or hla-a\*0206-restricted epitope peptides, which were derived from a cancer-testis antigen, urlc10, as targets for cancer vaccination against lung cancer. in this phase i trial, the investigators examine using a combination of these three peptides the safety, immunogenicity, and antitumor effect of vaccine treatment for hhla-a\*0201 or hla-a\*0206-positive advanced non-small cell lung cancer patients who failed to standard therapy.

Eligibility criteria:
inclusion criteria: 1. nsclc that can not undergo curative surgery and treatment, and is refractory to standard chemotherapy and radiotherapy 2. ecog performance status 0-2 3. age between 20 to 85 4. clinical efficacy can be evaluated by some methods 5. no prior chemotherapy, radiation therapy, hyperthermia or immunotherapy within 4 weeks 6. life expectancy \> 3 months 7. laboratory values as follows 1500/mm3 \ 75000/mm3 asparate transaminase \< 3 x cutoff value alanine transaminase \< 3 x cutoff value total bilirubin \< 3 x cutoff value serum creatinine \< 2x cutoff value 8. hla-a\*0201 or hla-a\*0206 9. able and willing to give valid written informed consent exclusion criteria: 1. active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia) 2. myocardial infarction within six months before entry 3. breastfeeding and pregnancy (woman of child bearing potential) 4. active and uncontrolled infectious disease 5. concurrent treatment with steroids or immunosuppressing agent 6. other malignancy requiring treatment 7. non-cured traumatic wound 8. decision of unsuitableness by principal investigator or physician-in-charge

Keywords: urlc10 lung cancer vaccine hla-a*0201 hla-a*0206
intermittent oral-esophageal tube in delayed dysphagia after radiotherapy for nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for npc. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (qol) after treatment as well as adverse events are compared.

palliation to delayed dysphagia after radiotherapy for nasopharyngeal carcinoma (npc) continues to be a challenge. although nasogastric tube feeding (ngt) has been adopted widely, the weaknesses have yet to be improved by another enteral nutrition support mode. this study aims to observe the clinical efficacy of intermittent oro-esophageal tube feeding (ioe) in the treatment of delayed dysphagia after radiotherapy for (npc). this is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for npc. patients enrolled are randomly divided equally into the observation group and the control group. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (qol) after treatment as well as adverse events are compared.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * with the history of nasopharyngeal carcinoma and radiation therapy. * with dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support. * conscious and with stable vital signs; * willing to participate and sign the written informed consent form either personally or by a family member. exclusion criteria: * presence of other diseases that might cause dysphagia. * with distant metastasis of tumors, or complicated with severe systemic disorders or malignancies. * concurrent participation in other treatments that could interfere with the trial. * inability to cooperate with treatment due to aphasia, mental health issues, etc. * received tube feeding for enteral nutrition support within the past three years.
effect of allulose on diet-induced thermogenesis

Conditions: Diet Induced Thermogenesis

Summary: the objective of this study is to investigate the dose-response effect of allulose on diet-induced thermogenesis, substrate oxidation, glycemic response, and subjective appetite in healthy normal weight adults.

a within-subject, repeated measures, randomized, repeated measures design will be used. participants (n= 10, 5 males, 5 females) will consume, in a random order, one of three varying doses of test treatments (allulose (5g), allulose (10g) or allulose (20g)) on 3 separate days. after treatment consumption, energy expenditure measurements via indirect calorimetry will be collected in 30-min interval (30-min measurement, 30-min rest) for 3 hours. blood glucose will be measured at baseline and continuously for 3 hours via the dexcom g6 continuous glucose monitoring system. subjective appetite (hunger, fullness, desire to eat, prospective food consumption) will be measured via visual analogue scales at baseline and at the end of each energy expenditure measurement interval over 3 hours.

Eligibility criteria:
inclusion criteria: * participants (18 - 45 years) who are considered healthy, are non-smokers, and have a body mass index (bmi) between 20 and 24.9 kg/m2 \[world health organization classification of normal weight bmi\]. exclusion criteria: * participants who have a fasting plasma glucose \> 5.5 mmol/l indicative of impaired fasting glucose, previously diagnosed diabetes, known or uncertain pregnancy status at the screening visit, gastrointestinal disease, liver or kidney disease, have undergone a major medical or surgical event within the past 6 months, were or are on a diet, skip breakfast, smoke or have taken medication which would be a potential confounder with effects on metabolic and intake regulation. * those unable to complete the testing protocols or are intolerant or allergic to test-day ingredients.

Keywords: adults allulose energy expenditure blood glucose appetite
prospective evaluation of notes (natural orifice translumenal endoscopic surgery) peg "rescue"

Conditions: Malnutrition

Summary: the purpose of this study is to determine: 1. utility of urgent upper endoscopy in setting of dislodges (percutaneous endoscopic gastrostomy) peg tube. 2. feasibility of replacing naive peg tubes with natural orifice translumenal endoscopic surgery (notes) in lieu of traditional surgical methods. 3. efficacy of replacing naive peg tubes with notes in lieu of traditional surgical methods.

1. utility of urgent upper endoscopy in setting of naïve dislodged peg tubes as defined by: * percentage of open vs. closed gastrotomy upon urgent endoscopy * presence of incidental pathology noted on endoscopy * complications of urgent endoscopy * time of procedure 2. technical feasibility of the notes procedure determined by: * number of successful/failed peg placements * number of patients requiring intra-operative conversion to laparotomy or laparoscopic procedure * time to complete procedure * presence or absence of post-procedural contrast extravasation on completion contrast radiographic study 3. efficacy of notes peg rescue compared to historical controls as characterized by the following post-operative criteria: * number of patients requiring subsequent medical or surgical treatment for intra-abdominal abscess * number of patients requiring subsequent medical or surgical wound infection within 30 post-op days * post-operative ct or operative findings consistent with abscess confirmed by culture positive drainage, aspiration * intra-operative or post-operative red blood cell transfusion * length of stay * antibiotics \> 24h post-op * 30 day re-admission * mortality

Eligibility criteria:
inclusion criteria: patients must meet all of the following criteria * for prospective candidates, an initial attempt to pass a balloon tipped foley catheter through the external cutaneous tract into the stomach will be performed. it will then be followed by radiographic contrast study to evaluate for extravasation of contrast into the peritoneal cavity. if contrast is extravasated, this will be potential candidate for inclusion. if the foley catheter is unable to be passed through the cutaneous tract, that will also be considered someone for inclusion as this patient will still require an operative confirmation of the patency of the gastrotomy. * for retrospective candidates, intra-operative confirmation of dislodged tube as reported in the medical record. * the patient must demonstrate pre-operative hemodynamic and respiratory stability * no overwhelming medical co-morbidities prohibitive of surgery * subject is 18 years of age or older * subject or subject's legal decision-making proxy agrees to participate, fully understands and signs the informed consent form exclusion criteria: patients must not meet any of the following criteria: * esophageal stricture prohibiting passage of an endoscope * any contraindication to surgery * pregnancy or actively breastfeeding women * evidence of active bowel obstruction * synchronous acute abdominal pathology warranting incision-based surgery

Keywords: dislodged peg tube notes
oxytocin versus, sublingual misoprostol in the secondary prevention of postpartum hemorrhage after vaginal delivery

Conditions: Labor Complication

Summary: researchers sought to see how oxytocin versus, sublingual misoprostol affected estimated and measured blood loss during vaginal delivery in women who had blood loss \>300 ml .

the greatest cause of maternal mortality globally is postpartum hemorrhage (pph), which is defined as a blood loss of 500 ml or more after birth. all women giving birth should be given a preventive uterotonic drug, according to the world health organization (who). despite the use of a uterotonic drug as a preventative measure, pph remains a frequent complication, accounting for one-quarter of all maternal fatalities worldwide. when prophylaxis fails and pph develops, it is advised that uterotonic medicines be used as first-line therapy. however, it's unclear whether the uterotonic drug is better for treating pph as first-line therapy.

Eligibility criteria:
inclusion criteria: * vaginal birth in women who had blood loss \>300 ml exclusion criteria: * \<37 weeks of pregnancy, * genital tract injuries, * coagulation deficit, * hypertension, preeclampsia, * cardiac, renal, or hepatic disease, * epilepsy,
influence of the proton pump inhibitor omeprazole on the anti-platelet of p2y12 antagonists in subjects with coronary and peripheral artery disease

Conditions: Coronary Artery Disease; Peripheral Artery Disease

Summary: to determine if prasugrel is superior to clopidogrel in providing adequate antiplatelet effect in a high risk population that requires concomitant use of a proton pump inhibitor (ppi).

to evaluate if simultaneous treatment with the ppi omeprazole and a p2y12 receptor antagonist will influence the effect of either clopidogrel and/or prasugrel on platelet reactivity in patients with coronary artery disease (cad) or peripheral arterial disease (pad).

Eligibility criteria:
inclusion criteria: * adults between 18 and 75 years of age * known or documented history of cad or pad prior to enrollment (a diagnosis of cad may be based upon a positive stress test, prior documented acute coronary event, or angiographic demonstration of cad; a diagnosis of pad may be based upon an ankle-brachial index less than 0.9, or angiographic demonstration of pad) * have not had thienopyridine therapy for at least 15 days before the study * have not had treatment with a ppi for at least 15 days before the study * are taking aspirin (75 to 325 mg/day) for at least one week prior to randomization exclusion criteria: * have new york heart association (nyha) class iii and iv congestive heart failure * have any form of coronary revascularization (pci or coronary artery bypass grafting \[cabg\]) planned to occur during the study * have undergone pci or cabg within 30 days of entry to the study * have received a drug eluting endovascular stents in the past year * have any of the following: 1. prior history of hemorrhagic stroke or transient ischemic attack (tia) 2. intracranial neoplasm, arteriovenous malformation, or aneurysm 3. a body weight less than 60 kg * have prior history of gi ulcer disease or bleeding * have symptoms of dyspepsia or gastroesophageal reflux disease * have active internal bleeding or history of bleeding diathesis * have clinical findings, in the judgment of the investigator, associated with an increased risk of bleeding * have an international normalized ratio (inr) known to be \>1.5 at the time of evaluation * have a platelet count of \<100,000/mm3 at the time of screening, if known * have anemia (hemoglobin \[hgb\] \<10 gm/dl) at the time of screening, if known * are receiving or will receive oral anticoagulation or other antiplatelet therapy (other than aspirin) that cannot be safely discontinued for the duration of the study * are receiving daily treatment with nonsteroidal anti-inflammatory drugs (nsaids) that cannot be discontinued or require daily treatment with nsaids during the study. * are receiving corticosteroid therapy
lap adhesiolysis in intestinal obstruction

Conditions: Adhesions Bowel

Summary: comparison between the results of laparotomy and laparoscopy in adhesive intestinal obstruction and introduce the use of laparoscopy to the emergency setting in asyut university hospital.

adhesive intestinal obstruction is one of the most common complications after any abdominal surgery. adhesions account for 75% of causes of intestinal obstruction. laparoscopic adhesiolysis recently increase in frequency over open adhesiolysis but there is no definit evidence of its superiority. in term of length of hospital stay and morbidity. adhesive bowel obstruction mainly managed by conservative treatment but some refractory cases needs surgical intervention in this study we will evaluate feasibility and efficacy of using laparoscop in adhesiolysis over open approach .

Eligibility criteria:
inclusion criteria: * any male or female above 18 years has adhesive intestinal obstruction * patient fulfilled the criteria to participate but operated before time of study if adequate data available * patient in which conservative management is failed exclusion criteria: * othe casues of intestinal obstruction (other than adhsions) * shocked patient * cardiovascular diseases * coagulopathy * liver cirrhosis * intracranial diseases
assessment of trunk aesthetics: development of a new tool

Conditions: Adolescent Idiopathic Scoliosis

Summary: scoliosis is a three-dimensional deformity of the spine and the trunk. trace (trunk aesthetic clinical evaluation) is an aesthetics assessment tool for patients with scoliosis. it has been validated with rasch analysis is easily usable in daily clinical practice. despite this tool being more sensitive in detecting changes in aesthetics during treatment compared to other existing ones, its reliability is still low, probably due to the small number of elements that make up the rating scale. this study aims to develop a new version of the trace tool by adding new items. the development of trace2 in a rasch environment will ensure greater sensitivity and specificity of the scale assessment.


Eligibility criteria:
inclusion criteria: * diagnosis of scoliosis * age between 10 and 17 years old * scoliosis \>10° cobb * humps \> 5° atr exclusion criteria: * history of spinal surgery * positive neurological assessment
benefits of individual physical activity intervention on health-related quality of life in participants with chronic lymphocytic leukemia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Summary: the purpose of this study is to assess the impact of an individual physical activity intervention (ipai) on health-related quality of life (hrqol) in participants with first line or relapsed chronic lymphocytic leukemia (cll) initiating ibrutinib in a routine clinical practice setting. hrqol will be measured using functional assessment of cancer therapy - general scale (fact-g).


Eligibility criteria:
inclusion criteria: * participants newly treated with ibrutinib for first line or relapsed cll (treatment is being initiated or has been initiated within the last 8 days as a maximum) * participants agreed to follow the individual physical activity intervention (ipai) * participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet * participants with internet access at home and email address * participants agreed to wear a connected watch 24 hours a day for all the duration of the study exclusion criteria: * pregnant participants or planning to become pregnant while enrolled in this study * participants with inability or deemed unsafe to practice physical activity * participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit * participants who are currently involved in an interventional study * participants with probable difficulties in using the digital tool autonomously